Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction.

Favier AL, Reynard O, Gout E, van Eijk M, Haagsman HP, Crouch E, Volchkov V, Peyrefitte C, Thielens NM.

Viruses. 2018 Dec 26;11(1). pii: E15. doi: 10.3390/v11010015.

2.

Mannoside Glycolipid Conjugates Display Antiviral Activity Against Ebola Virus.

Reynard O, Schaeffer E, Volchkova VA, Cimarelli A, Mueller CG, Volchkov VE.

J Infect Dis. 2018 Nov 22;218(suppl_5):S666-S671. doi: 10.1093/infdis/jiy464.

PMID:
30239745
3.

Filovirus proteins for antiviral drug discovery: Structure/function of proteins involved in assembly and budding.

Martin B, Reynard O, Volchkov V, Decroly E.

Antiviral Res. 2018 Feb;150:183-192. doi: 10.1016/j.antiviral.2017.12.022. Epub 2018 Jan 2. Review.

PMID:
29305306
4.

Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.

Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, Burlaud Gaillard J, Confort MP, Escudero-Perez B, Gruffat H, Hong SS, Moroso M, Reynard O, Reynard S, Decembre E, Ftaich N, Rossi A, Wu N, Arnaud F, Baize S, Dreux M, Gerlier D, Paranhos-Baccala G, Volchkov V, Roingeard P, Cimarelli A.

PLoS Pathog. 2017 Sep 28;13(9):e1006610. doi: 10.1371/journal.ppat.1006610. eCollection 2017 Sep.

5.

Modeling Ebolavirus Budding with Virus Like Particles.

Reynard O, Mateo M.

Methods Mol Biol. 2017;1628:109-117. doi: 10.1007/978-1-4939-7116-9_8.

PMID:
28573614
6.

Human transmission of Ebola virus.

Lawrence P, Danet N, Reynard O, Volchkova V, Volchkov V.

Curr Opin Virol. 2017 Feb;22:51-58. doi: 10.1016/j.coviro.2016.11.013. Epub 2016 Dec 22. Review.

PMID:
28012412
7.

Characterization of the Unconventional Secretion of the Ebola Matrix Protein VP40.

Reynard O, Mateo M.

Methods Mol Biol. 2016;1459:205-13. doi: 10.1007/978-1-4939-3804-9_14.

PMID:
27665561
8.

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.

Reynard O, Jacquot F, Evanno G, Mai HL, Salama A, Martinet B, Duvaux O, Bach JM, Conchon S, Judor JP, Perota A, Lagutina I, Duchi R, Lazzari G, Le Berre L, Perreault H, Lheriteau E, Raoul H, Volchkov V, Galli C, Soulillou JP.

PLoS One. 2016 Jun 9;11(6):e0156775. doi: 10.1371/journal.pone.0156775. eCollection 2016.

9.

Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.

Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP, Volchkov V, Peyrefitte C, Thielens NM.

J Virol. 2016 May 12;90(11):5256-5269. doi: 10.1128/JVI.00232-16. Print 2016 Jun 1.

10.

Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication.

Reynard O, Nguyen XN, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov VE.

Viruses. 2015 Dec 1;7(12):6233-40. doi: 10.3390/v7122934. Erratum in: Viruses. 2016;8(5). pii: E137. doi: 10.3390/v8050137.

11.

Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.

Reynard O, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S372-8. doi: 10.1093/infdis/jiv303. Epub 2015 Aug 1.

PMID:
26232760
12.

RNA Editing of the GP Gene of Ebola Virus is an Important Pathogenicity Factor.

Volchkova VA, Dolnik O, Martinez MJ, Reynard O, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S226-33. doi: 10.1093/infdis/jiv309. Epub 2015 Jul 2.

PMID:
26138826
13.

Entry of Ebola Virus is an Asynchronous Process.

Reynard O, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S199-203. doi: 10.1093/infdis/jiv189. Epub 2015 May 3.

PMID:
25941332
14.

[Haemostasis dysregulation in filovirus infections].

Reynard O, Escudero-Perez B, Volchkov V.

Med Sci (Paris). 2015 Feb;31(2):143-50. doi: 10.1051/medsci/20153102010. Epub 2015 Mar 4. Review. French.

15.

[A first outbreak of Ebola virus in West Africa].

Reynard O, Volchkov V, Peyrefitte C.

Med Sci (Paris). 2014 Jun-Jul;30(6-7):671-3. doi: 10.1051/medsci/20143006018. Epub 2014 Jul 11. French. No abstract available.

16.

Marburgvirus hijacks nrf2-dependent pathway by targeting nrf2-negative regulator keap1.

Page A, Volchkova VA, Reid SP, Mateo M, Bagnaud-Baule A, Nemirov K, Shurtleff AC, Lawrence P, Reynard O, Ottmann M, Lotteau V, Biswal SS, Thimmulappa RK, Bavari S, Volchkov VE.

Cell Rep. 2014 Mar 27;6(6):1026-1036. doi: 10.1016/j.celrep.2014.02.027. Epub 2014 Mar 13.

17.

Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry.

Leung LW, Martinez O, Reynard O, Volchkov VE, Basler CF.

J Infect Dis. 2011 Nov;204 Suppl 3:S973-7. doi: 10.1093/infdis/jir331.

18.

Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs.

Volchkova VA, Dolnik O, Martinez MJ, Reynard O, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S941-6. doi: 10.1093/infdis/jir321.

PMID:
21987773
19.

Role of VP30 phosphorylation in the Ebola virus replication cycle.

Martinez MJ, Volchkova VA, Raoul H, Alazard-Dany N, Reynard O, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S934-40. doi: 10.1093/infdis/jir320.

PMID:
21987772
20.

Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication.

Mateo M, Carbonnelle C, Martinez MJ, Reynard O, Page A, Volchkova VA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S892-6. doi: 10.1093/infdis/jir311.

PMID:
21987766
21.

Conserved proline-rich region of Ebola virus matrix protein VP40 is essential for plasma membrane targeting and virus-like particle release.

Reynard O, Nemirov K, Page A, Mateo M, Raoul H, Weissenhorn W, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S884-91. doi: 10.1093/infdis/jir359.

PMID:
21987765
22.

Unconventional secretion of Ebola virus matrix protein VP40.

Reynard O, Reid SP, Page A, Mateo M, Alazard-Dany N, Raoul H, Basler CF, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S833-9. doi: 10.1093/infdis/jir305.

23.

Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1060-5. doi: 10.1093/infdis/jir347.

24.

VP24 is a molecular determinant of Ebola virus virulence in guinea pigs.

Mateo M, Carbonnelle C, Reynard O, Kolesnikova L, Nemirov K, Page A, Volchkova VA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1011-20. doi: 10.1093/infdis/jir338.

PMID:
21987737
25.

The human metapneumovirus matrix protein stimulates the inflammatory immune response in vitro.

Bagnaud-Baule A, Reynard O, Perret M, Berland JL, Maache M, Peyrefitte C, Vernet G, Volchkov V, Paranhos-Baccalà G.

PLoS One. 2011 Mar 11;6(3):e17818. doi: 10.1371/journal.pone.0017818.

26.

Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF.

J Virol. 2010 Mar;84(6):3004-15. doi: 10.1128/JVI.02459-09. Epub 2010 Jan 13.

27.

Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins.

Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, Volchkov VE.

J Virol. 2009 Sep;83(18):9596-601. doi: 10.1128/JVI.00784-09. Epub 2009 Jul 8.

28.

Role of Ebola virus VP30 in transcription reinitiation.

Martínez MJ, Biedenkopf N, Volchkova V, Hartlieb B, Alazard-Dany N, Reynard O, Becker S, Volchkov V.

J Virol. 2008 Dec;82(24):12569-73. doi: 10.1128/JVI.01395-08. Epub 2008 Oct 1.

29.

Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level.

Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, Ottmann M, Khromykh A, Volchkov VE.

J Gen Virol. 2006 May;87(Pt 5):1247-57.

PMID:
16603527
30.

VP40 octamers are essential for Ebola virus replication.

Hoenen T, Volchkov V, Kolesnikova L, Mittler E, Timmins J, Ottmann M, Reynard O, Becker S, Weissenhorn W.

J Virol. 2005 Feb;79(3):1898-905.

31.

In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity.

Vicari AP, Vanbervliet B, Massacrier C, Chiodoni C, Vaure C, Aït-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchieri G, Caux C.

Novartis Found Symp. 2004;256:241-54; discussion 254-69. Review.

PMID:
15027495
32.

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.

Vicari AP, Chiodoni C, Vaure C, Aït-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchieri G, Caux C.

J Exp Med. 2002 Aug 19;196(4):541-9.

Supplemental Content

Loading ...
Support Center